| Simultaneous quantification of c-myc oncoprotein, total cellular protein, and DNA content using multiparameter flow cytometry. | None |
| Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. | None |
| Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. | None |
| low levels of deregulated Myc are competent to drive ectopic proliferation of somatic cells and oncogenesis, but activation of the apoptotic and ARF/p53 intrinsic tumor surveillance pathways requires Myc overexpression | None |
| Characteristics of an infinite life span diploid human fibroblast cell strain and a near-diploid strain arising from a clone of cells expressing a transfected v-myc oncogene. | None |
| IFI16 and NM23 bind to a common DNA fragment both in the P53 and the cMYC gene promoters. | None |
| Chromosomal location targets different MYC family gene members for oncogenic translocations. | None |
| Far upstream element-binding protein-1, a novel caspase substrate, acts as a cross-talker between apoptosis and the c-myc oncogene. | None |
| Transgenic animals as a tool for studying the effect of the c-myc proto-oncogene on cardiac development. | None |
| 3D view to tumor suppression: Lkb1, polarity and the arrest of oncogenic c-Myc. | None |
| HeLaTG cells have mitochondrial DNA inserted into the c-myc oncogene. | None |
| The v-abl, c-fms, or v-myc oncogene induces gamma radiation resistance of hematopoietic progenitor cell line 32d cl 3 at clinical low dose rate. | None |
| Both OH-2 and primary cells have a complex secondary translocation in which the IGK 3_ enhancer is inserted between MYC and MAFB, resulting in dysregulation of both oncogenes | None |
| [In vitro studies on the expression of c-myc oncogene product in gynecological cultured cancer cells]. | None |
| Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. | None |
| Data reveal a central organizing function for the Myc oncogene in the metabolism of cycling cells, and the pervasive deregulation of c-Myc in human cancers may be explained by its function in directing metabolic networks required for cell proliferation. | None |
| Facilitating replication under stress: an oncogenic function of MYC?. | None |
| The alleles of rs6983267 differentially bind transcription factor 7-like 2 (TCF7L2) and the risk region physically interacts with the MYC proto-oncogene. | None |
| C-myc could be another protooncogene in fibrous dysplasia. | None |
| [Abnormal expression of c-myc, p53, p16 protein and GNAS1 gene mutation in fibrous dysplasia]. | None |